APA (7th ed.) Citation

Silberstein, S. D., Stauffer, V. L., Day, K. A., Lipsius, S., & Wilson, M. (2019). Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). Journal of headache and pain, 20(1), 118-2. https://doi.org/10.1186/s10194-019-1069-x

Chicago Style (17th ed.) Citation

Silberstein, Stephen D., Virginia L. Stauffer, Katie A. Day, Sarah Lipsius, and Maria-Carmen Wilson. "Correction to: Galcanezumab in Episodic Migraine: Subgroup Analyses of Efficacy by High Versus Low Frequency of Migraine Headaches in Phase 3 Studies (EVOLVE-1 & EVOLVE-2)." Journal of Headache and Pain 20, no. 1 (2019): 118-2. https://doi.org/10.1186/s10194-019-1069-x.

MLA (9th ed.) Citation

Silberstein, Stephen D., et al. "Correction to: Galcanezumab in Episodic Migraine: Subgroup Analyses of Efficacy by High Versus Low Frequency of Migraine Headaches in Phase 3 Studies (EVOLVE-1 & EVOLVE-2)." Journal of Headache and Pain, vol. 20, no. 1, 2019, pp. 118-2, https://doi.org/10.1186/s10194-019-1069-x.